Brand Name :
Paxlovid
Synonyms :
nirmatrelvir/ritonavir
Class :
SARS-CoV-2, Antivirals
Dosage Forms & Strengths
Tablets
300mg nirmatrelvir/100mg ritonavir dose pack- Each daily blister card comes with 2 ritonavir tablets-(100 mg) and 4 nirmatrelvir tablets-(150 mg)
150mg nirmatrelvir/100mg ritonavir dose pack-
Two nirmatrelvir (150 mg) tablets and two ritonavir (100 mg) tablets are included in each daily blister card
Paxlovid received full FDA-approval for Adult Dose; which is used to treat mild to moderate coronavirus disease 2019 (COVID-19) who are at a level of high risk of developing severe coronavirus disease, which might result in hospitalisation or death, EUA is no longer applicable.
Two 150 mg tablets of nirmatrelvir and one 100 mg tablet of ritonavir, totalling of 3 tablets, should be taken orally twice a day for five days
Note:
• Immediately start using this drug within 5 days after the onset of symptoms and as soon as COVID-19 has been diagnosed
• If hospitalization is required due to severe/critical coronavirus disease 2019 (COVID-19) after starting with this product, the patient need to complete the course of 5-day treatment as per health care provider's discretion
Dosage Forms & Strengths
Tablets
300mg nirmatrelvir/100mg ritonavir dose pack- Each daily blister card comes with 2 ritonavir tablets-(100 mg) and 4 nirmatrelvir tablets-(150 mg)
150mg nirmatrelvir/100mg ritonavir dose pack-
Two nirmatrelvir (150 mg) tablets and two ritonavir (100 mg) tablets are included in each daily blister card
Two 150 mg tablets of nirmatrelvir and one 100 mg tablet of ritonavir, totalling of 3 tablets, should be taken orally twice a day for five days
Note:
The US FDA issued an EUA to permit the use of pediatric dose to treat COVID-19 in an emergency with mild to moderate coronavirus disease 2019 (COVID-19) who are at a high risk of developing severe coronavirus disease, which might result in hospitalisation or death. Only those aged 12 to 18 years who weigh at least 40 kg are intended for investigational use
Refer adult dosing
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration
may enhance the serum concentration of P-glycoprotein/ABCB 1 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of P-glycoprotein/ABCB 1 inhibitors
may enhance the serum concentration
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may diminish the serum concentration
may diminish the serum concentration
may diminish the serum concentration
may diminish the serum concentration
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of P-glycoprotein/ABCB 1 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
nirmatrelvir and ritonavir: they may diminish the serum concentration of hormonal contraceptives
nirmatrelvir and ritonavir: they may diminish the serum concentration of hormonal contraceptives
nirmatrelvir and ritonavir: they may diminish the serum concentration of hormonal contraceptives
nirmatrelvir and ritonavir: they may diminish the serum concentration of hormonal contraceptives
azelastine/fluticasone intranasal
may enhance the serum concentration
may decrease the therapeutic effect of each other when combined
may enhance the serum concentration when combined
may diminish the serum concentration of Hormonal Contraceptives
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration
may enhance the serum concentration of CYP3A4 inhibitors
may diminish the serum concentration
may diminish the serum concentration
may diminish the serum concentration
may diminish the serum concentration
may diminish the serum concentration
may enhance the serum concentration
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may diminish the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the concentration of serum when combined with salmeterol
may decrease the therapeutic effect when combined
may diminish the serum concentration
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may diminish the serum concentration
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may diminish the serum concentration
may diminish the serum concentration of protease inhibitors
may diminish the serum concentration of protease inhibitors
may enhance the serum concentration of nirmatrelvir and ritonavir
may enhance the serum concentration of nirmatrelvir and ritonavir
may enhance the serum concentration of nirmatrelvir and ritonavir
may enhance the serum concentration of nirmatrelvir and ritonavir
may enhance the serum concentration of nirmatrelvir and ritonavir
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the serum concentration when combined with corticosteroids
may enhance the serum concentration when combined with corticosteroids
may enhance the serum concentration when combined with corticosteroids
may enhance the serum concentration when combined with corticosteroids
may enhance the serum concentration when combined with corticosteroids
antiviral agents (HCV): they may increase the hypoglycemic effect of antidiabetic drugs
nirmatrelvir and ritonavir: they may enhance the serum concentration of corticosteroids
may enhance the serum concentration of nirmatrelvir and ritonavir
may increase the hypoglycemic effect of Antidiabetic Agents
may increase the hypoglycemic effect of Antidiabetic Agents
may increase the Glucose-lowering effect of Antidiabetic Agents
fusidic acid and betamethasone
may enhance the serum concentration when combined
framycetin, dexamethasone, and gramicidin
may enhance the serum concentration when combined
Actions and Spectrum:
Paxlovid may have a synergistic effect against SARS-CoV-2. ritonavir is used in combination with nirmatrelvir to increase its concentration in the body and prolong its effectiveness by inhibiting certain enzymes responsible for metabolizing nirmatrelvir. This combination is intended to enhance the antiviral activity and duration of action of nirmatrelvir against SARS-CoV-2.
Frequency defined
1-10%
Diarrhea
Myalgia
Dysgeusia
Hypertension
Post authorization experience
Abdominal pain
Hypersensitivity reactions
Malaise
Black Box Warning:
No information available
Contraindication / Caution:
Pregnancy consideration: Insufficient data available
Lactation: Excretion of the drug in human breast milk is Unknown (nirmatrelvir); known (ritonavir)
Pregnancy category:
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Administration:
nirmatrelvir/ritonavir is an oral medication that comes in tablet form. It is typically taken by mouth with food to improve absorption. The specific dosage and duration of treatment can vary depending on several factors, including the severity of the infection, the patient’s age, weight, and overall health, as well as the prescribing doctor’s recommendation.
Patient information leaflet
Generic Name: nirmatrelvir/ritonavir
Pronounced: nur-MA-trəl-vee/ ri-tonavir
